title: [Inflammatory response in acute myocardial infarction. Predictive values].
abstract: OBJECTIVE
  Our purpose was to investigate the significance of inflammatory acute phase response early after myocardial infarction. We also observed how these indices were influenced by trombolytic therapy.
  
  
  METHODS
  We examined the blood samples of 200 non consecutive patients at the first day of acute myocardial infarction (155 [77%] males; mean age 65 +/- 13 years) to characterize the proteins and proinflamatory reactants profile. Results were correlated with hospital mortality. Thrombolytic therapy was administrated to 117 patients on admission and in these patients the samples were taken after the procedure.
  
  
  RESULTS
  Overall mortality was 8%. Serum C-reactive protein (69 vs 41 mg/l), haptoglobine (237 vs 190 mg/dl), gammaglobuline (0.93 vs 0.84 g/dl), alpha-1-globuline (0.28 vs 0.23 g/dl) and alpha-2-globuline (0.7 vs 0.6 g/dl) were significantly higher in patients without trombolytic therapy. Conversely, patients who had received lytic therapy, had higher plasma concentrations of interleukin-1 beta (104 vs 40 pg/dl). The only clinical variable which was associated with mortality was a Killip class > or = 2 on admission (mortality = 21%; odds ratio = 5.2; p = 0.02). Other biochemical variables associated with a higher mortality were a white blood cell count > 10/nl (mortality = 12%; odds ratio = 5.4; p = 0.01), increased activated neutrophils > 80% (mortality = 18%; odds ratio = 5.4; p = 0.004) and C-reactive protein > 20 mg/l (mortality = 11%; odds ratio = 6; p = 0.05). Only patients with activated neutrophils > 80% on admission had a higher probability of dying during hospital stay (Exp[B] = 3.6; B = 1.2; r = 0.29; p = 0.001).
  
  
  CONCLUSIONS
  The acute phase reaction in early myocardial infarction is determined by thrombolytic treatment. A high increase of activated neutrophils on patient admission is the only biochemical predictive value for hospital mortality.
authors.affiliation: Unidad Coronaria, Hospital Clínico Universitario, Valencia.
authors.forename: R
authors.initials: R
authors.lastname: Sanjuán Máñez
authors.forename: M
authors.initials: M
authors.lastname: Blasco Cortés
authors.forename: J
authors.initials: J
authors.lastname: Muñoz Gil
authors.forename: C
authors.initials: C
authors.lastname: Gimeno Cardona
authors.forename: F
authors.initials: F
authors.lastname: Savall Calvo
authors.forename: J
authors.initials: J
authors.lastname: Ferreres Franco
authors.forename: V
authors.initials: V
authors.lastname: Bodí Peris
authors.forename: J
authors.initials: J
authors.lastname: Samper Codes
authors.forename: S
authors.initials: S
authors.lastname: Morell Cabedo
authors.forename: V
authors.initials: V
authors.lastname: López Merino
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003627:Data Interpretation, Statistical; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D009205:Myocarditis / Q000188:drug therapy / Q000209:etiology*; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D015912:Thrombolytic Therapy / Q000379:methods
chemical_list: D005343:Fibrinolytic Agents